AF
MBIO icon

Amalgamated Financial’s Mustang Bio MBIO Stock Holding History

Amalgamated Financial’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$9K Buy
+12
New +$9.86K ﹤0.01% 2911

Other funds holding MBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's MBIO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Mustang Bio (MBIO) in Q1 2022: 12 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2911 among its holdings.

81 funds tracked by Wall St. Rank hold MBIO as of Q1 2022.

  • Amalgamated Financial held 12 shares of Mustang Bio worth $9K as of Q1 2022.
  • Mustang Bio was a new Amalgamated Financial position in Q1 2022.
  • Mustang Bio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2911 holding.
  • 81 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.